GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

PGR · Mar 31, 2026

PROGRESSIVE CORP/OH/. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0000080661-26-000177Insurance
Cash53thOwn-history percentile · N=15
Evidence method

Level · gp.fundamentals.cash

$179.0M · CORE · VALID

Policy-benefit growthRAWCurrent state valid · history insufficient
Evidence method

Yoy · gp.insurance.policy_benefits

7.99% · OPTIONAL · NOT_ENOUGH_HISTORY

Net-income growth0thOwn-history percentile · N=10
Evidence method

Yoy · gp.fundamentals.net_income

9.78% · CORE · VALID

Premium growthRAWCurrent state valid · history insufficient
Evidence method

Yoy · gp.insurance.premiums

8.03% · CORE · NOT_ENOUGH_HISTORY

Revenue growth0thOwn-history percentile · N=11
Evidence method

Yoy · gp.fundamentals.revenue

8.72% · CORE · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History12 statesSelf-history eligible
Period transition

What moved in the state?

Cash Increased
Previous
$138.0M
Current
$179.0M
Delta
$41.0M
Claims Growth Decreased
Previous
9.99%
Current
7.99%
Delta
-2.00%
Earnings Growth Decreased
Previous
33.35%
Current
9.78%
Delta
-23.57%
Premium Growth Decreased
Previous
15.34%
Current
8.03%
Delta
-7.31%
Revenue Growth Decreased
Previous
16.32%
Current
8.72%
Delta
-7.60%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.